Oxford BioMedica signs major supply deal with Novartis
admin 7th July 2017 Uncategorised 0Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
More: Oxford BioMedica signs major supply deal with Novartis
Source: News